Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans receive seasonal influenza shots that are free from the mercury-based ...

The CDC’s ACIP has blessed Merck’s new RSV shot Enflonsia, but the decision was not resounding from Robert F. Kennedy Jr.’s new panel of experts.

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

ACIP recommends use of Merck’s Enflonsia™ (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age born ...

Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions. The ACIP ...